291 Phase Ib study of selicrelumab (CD40 agonist) in combination with atezolizumab (anti-PD-L1) in patients with advanced solid tumors
Fabrice Barlesi, Martijn Lolkema, Kristoffer Staal Rohrberg, Cinta Hierro, Aurelien Marabelle, Albiruni Abdul Razak, Luis Teixeira, Valentina Boni, Wilson H Miller, Charu Aggarwal, Martin Stern, Olivera Cirovic, Olivera Cirovic, Barbara Romagnoli, Randolph Christen, Raksha Dodia, Kevin Smart, Bernhard Reis, Nicolas Staedler, Carl Watson, Neeltje Steeghs
Journal for ImmunoTherapy of Cancer Nov 2020, 8 (Suppl 3) A178; DOI: 10.1136/jitc-2020-SITC2020.0291